Read more about how indirect treatment comparisons (NMA, MAIC, and STC) were used to compare the relative efficacy of inotuzumab ozogamicin and blinatumomab for the treatment of adults with relapsed/refractory B cell precursor acute lymphoblastic leukemia:
RT @evideraglobal: An NMA, STC, and MAIC were conducted to compare two therapies for the treatment of adults with relapsed or refractory B…
An NMA, STC, and MAIC were conducted to compare two therapies for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia. Learn more in this publication: https://t.co/9mZbv5sFLs https://t.co/hGGSEnXzjG